Agilent Technologies Inc vs TransMedics Group Inc — how do they compare? Agilent Technologies Inc trades at $149.5 (market cap $42.22B), while TransMedics Group Inc trades at $89.19 (market cap $3.10B). The key difference: Agilent Technologies Inc is far larger — about 13.6× TransMedics Group Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| A | TMDX | |
|---|---|---|
Market Cap | $42.22B | $3.10B |
Sector | Health | Technology |
52-Week High | $157.20 | $150.42 |
52-Week Low | $110.24 | $61.99 |
Enterprise Value | $43.77B | $3.49B |
Dividend Yield | 0.68% | — |
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →